Q32 Bio closes Homology merger and $42M private placement
What's the deal? Q32 Bio completed its merger with Homology Medicines on March 25, 2024. The combined company began trading on Nasdaq under the ticker QTTB on March 26, 2024, while Q32 Bio also completed a $42 million private placement.
Who's involved? The placement included existing and new investors such as OrbiMed, Atlas Venture, AbingworthDealroom has a profile for this one. Try Dealroom →, Bristol Myers SquibbDealroom has a profile for this one. Try Dealroom →, Acorn BioventuresDealroom has a profile for this one. Try Dealroom →, Sanofi VenturesDealroom has a profile for this one. Try Dealroom →, Osage University PartnersDealroom has a profile for this one. Try Dealroom →, CU Healthcare Innovation FundDealroom has a profile for this one. Try Dealroom → and Agent CapitalDealroom has a profile for this one. Try Dealroom →.
Why now? Following the transactions, Q32 Bio reported approximately $130 million in cash, cash equivalents and investments, expected to fund operations through mid-2026. The company planned to advance bempikibart (ADX-914) in Phase 2 trials for atopic dermatitis and alopecia areata, alongside ADX-097, a tissue-targeted complement inhibitor entering Phase 2 development.
The signal: Q32 Bio's reverse merger with a listed biotech combined a Nasdaq listing with fresh capital for clinical development, a route that lets private drug developers access public markets while funding near-term milestones.
Read more: OrbiMed
Image credit: National Institutes of Health (NIH)
